Publicaciones científicas

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression

Mota A (1,2), Triviño JC (3), Rojo-Sebastian A (4), Martínez-Ramírez Á (5), Chiva L (6), González-Martín A (7), Garcia JF (8,9), Garcia-Sanz P (10,11), Moreno-Bueno G (12,13). (1) Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain.
(2) MD Anderson International Foundation, Madrid, Spain.
(3) Sistemas Genómicos, Valencia, Spain.
(4) Department of Pathology, MD Anderson Cancer Center, Madrid, Spain.
(5) Department of Molecular Cytogenetics, MD Anderson Cancer Center, Madrid, Spain.
(6) Department of Gynecologic Oncology, MD Anderson Cancer Center, Madrid, Spain.
(7) Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain.
(8) MD Anderson International Foundation, Madrid, Spain. jfgarcia@mdanderson.es.
(9) Department of Pathology, MD Anderson Cancer Center, Madrid, Spain.
(10) Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain.
(11) MD Anderson International Foundation, Madrid, Spain.
(12) Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain. 
(13) MD Anderson International Foundation, Madrid, Spain 

Revista: BMC Cancer

Fecha: 01-nov-2015

Ginecología y Obstetricia

BACKGROUND:

High grade serous ovarian cancer is characterised by high initial response to chemotherapy but poor outcome in the long term due to acquired resistance. One of the main genetic features of this disease is TP53 mutation. The majority of TP53 mutated tumors harbor missense mutations in this gene, correlated with p53 accumulation.

TP53 null tumors constitute a specific subgroup characterised by nonsense, frameshift or splice-site mutations associated to complete absence of p53 expression. Different studies show that this kind of tumors may have a worse prognosis than other TP53 mutated HGSC.

METHODS:

In this study, we sought to characterise the intra-tumor heterogeneity of a TP53 null HGSC consisting of six primary tumor samples, two intra-pelvic and four extra-pelvic recurrences using exome sequencing and comparative genome hybridisation.

RESULTS:

Significant heterogeneity was found among the different tumor samples, both at the mutational and copy number levels. Exome sequencing identified 102 variants, of which only 42 were common to all three samples; whereas 7 of the 18 copy number changes found by CGH analysis were presented in all samples.

Sanger validation of 20 variants found by exome sequencing in additional regions of the primary tumor and the recurrence allowed us to establish a sequence of the tumor clonal evolution, identifying those populations that most likely gave rise to recurrences and genes potentially involved in this process, like GPNMB and TFDP1.

Using functional annotation and network analysis, we identified those biological functions most significantly altered in this tumor. Remarkably, unexpected functions such as microtubule-based movement and lipid metabolism emerged as important for tumor development and progression, suggesting its potential interest as therapeutic targets.

CONCLUSIONS:

Altogether, our results shed light on the clonal evolution of the distinct tumor regions identifying the most aggressive subpopulations and at least some of the genes that may be implicated in its progression and recurrence, and highlights the importance of considering intra-tumor heterogeneity when carrying out genetic and genomic studies, especially when these are aimed to diagnostic procedures or to uncover possible therapeutic strategies.

CITA DEL ARTÍCULO  BMC Cancer. 2015 Nov 30;15:940. doi: 10.1186/s12885-015-1952-z.

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra